Gamble Jones Investment Counsel’s Alaunos Therapeutics TCRT Stock Holding History

Gamble Jones Investment Counsel’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$39.6K	Hold	407	–	–	﹤0.01%	202
2022 Q3	$105K	Hold	407	–	–	0.01%	211
2022 Q2	$76K	Hold	407	–	–	0.01%	203
2022 Q1	$40K	Hold	407	–	–	﹤0.01%	209
2021 Q4	$66K	Buy	407 +200	+97%	+$44K	﹤0.01%	214
2021 Q3	$56K	Hold	207	–	–	﹤0.01%	213
2021 Q2	$82K	Hold	207	–	–	0.01%	217
2021 Q1	$112K	Hold	207	–	–	0.01%	212
2020 Q4	$78K	Hold	207	–	–	0.01%	207
2020 Q3	$78K	Hold	207	–	–	0.01%	203
2020 Q2	$102K	Buy	207 +7	+4%	+$3.12K	0.01%	197
2020 Q1	$74K	Buy	200 +13	+7%	+$6.73K	0.01%	187
2019 Q4	$132K	Hold	187	–	–	0.01%	209
2019 Q3	$120K	Hold	187	–	–	0.01%	199
2019 Q2	$163K	Sell	187 -13	-7%	-$8.94K	0.01%	207
2019 Q1	$116K	Hold	200	–	–	0.01%	206
2018 Q4	$56K	Buy	+200	New	+$79.1K	0.01%	207

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return

SGCA

Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Gamble Jones Investment Counsel's TCRT Position: Q4 2022 in Review

Gamble Jones Investment Counsel held its Alaunos Therapeutics (TCRT) position steady in Q4 2022 at 407 shares worth $39.6K. The position accounts for ﹤0.01% of the portfolio, ranked #202.

Gamble Jones Investment Counsel first reported a position in TCRT in Q4 2018 and has held it in 17 quarters since. The position peaked at $163K in Q2 2019. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

Gamble Jones Investment Counsel held 407 shares of Alaunos Therapeutics worth $39.6K as of Q4 2022.
Gamble Jones Investment Counsel left its Alaunos Therapeutics share count unchanged in Q4 2022.
Alaunos Therapeutics made up ﹤0.01% of Gamble Jones Investment Counsel's portfolio in Q4 2022, its #202 holding.
Gamble Jones Investment Counsel first reported a position in Alaunos Therapeutics in Q4 2018 and has held it in 17 quarters since.
Gamble Jones Investment Counsel's Alaunos Therapeutics position peaked at $163K in Q2 2019.
122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Gamble Jones Investment Counsel's 13F filing for Q4 2022, filed 8 Feb 2023.